Global private equity and venture capital news and research

Posts Tagged ‘Novo Ventures’

24 November 2015

Serious pregnancy condition drug developer nabs CHF60m VC-backed Series B

pregnant-244662_1920 Swiss biopharmaceutical company ObsEva, which develops drugs focusing on serious conditions compromising pregnancy, has raised a CHF60m ($59m) Series B round from a string of venture capital firms.

16 February 2015

VC trio lead $25m Series A life sciences tools startup Unchained Labs

download (32) Novo Ventures, Canaan Partners and TPG Biotech have led a $25m Series a financing round in California-based life sciences tools startup Unchained Labs.

2 October 2014

Venture capital-backed Alios BioPharma sold to Johnson & Johnson for $1.75bn

sale-1306463-m Clinical stage biopharmaceutical company Alios BioPharma has been bought by multinational healthcare business Johnson & Johnson for around $1.75bn in cash.

30 April 2014

Anti-ear disorder company Otonomy attracts more venture capital in $49m Series D

ear_lrg Venture-backed ear disorder treatment business Otonomy has picked up another $49m of funding through an oversubscribed Series D round.

16 April 2014

Biopharma developer PanOptica scores $45m Series B investment

Biopharmaceutical company PanOptica has raised up to $45m in a Series B financing, co-led by new participant Novo Ventures and existing investor Third Rock Ventures, alongside founding investor SV Life Sciences.

9 April 2014

Mystery investor joins venture backers in $41m Alios BioPharma Series B

virus2_sq A string of venture capital firms have renewed their backing of biotech business Alios BioPharma to help it develop treatments for respiratory viral diseases.

25 February 2014

Novo Ventures leads $49m Series B for anti-acne business Thesan Pharmaceuticals

skin5_lrg Biotechnology business Thesan Pharmaceuticals, which aims to treat skin disorders including acne and dermatitis, has picked up $49m of Series B financing led by existing backer Novo Ventures.

7 March 2013

VC firm Novo leads $48m round for Nevro Corp

news_biotech_lrg Venture capital firm Novo Ventures has thrown its support behind Nevro Corp by leading its sizeable $48m Series C funding round, which was also supported by peers Enterprise Associates and Covidien Ventures.

17 December 2012

Novo Ventures leads $32m financing for biotech company Allakos

virus2_sq Denmark-based Novo Ventures has led a $32m Series A preferred stock financing round for antibody-focused biotechnology company Allakos.

31 October 2012

Novo, Novartis lead $16m Series A for Thesan Pharmaceuticals

Thesan Pharmaceuticals has closed a $16m Series A round, co-led by corporate investment group Novo Ventures and life sciences-focused Novartis Venture Funds.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016